"Receptor, trkB" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A protein-tyrosine kinase receptor that is specific for BRAIN-DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIN 3; neurotrophin 4 and neurotrophin 5. It is widely expressed in nervous tissue and plays a role in mediating the effects of neurotrophins on growth and differentiation of neuronal cells.
| Descriptor ID |
D020813
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.700 D12.776.543.750.630.498 D12.776.543.750.750.400.550.600
|
| Concept/Terms |
Receptor, trkB- Receptor, trkB
- BDNF Receptor
- Receptor, BDNF
- trkB Receptor
- Receptor, Neurotrophic Tyrosine Kinase Type 2
- NTRK2 Receptor
- Receptor, NTRK2
- Brain Derived Neurotrophic Factor Receptor
- Neurotrophic Tyrosine Kinase Receptor Type 2
- trkB(gp145) Protein
- Neurotrophic Factor, Brain-Derived, Receptor
|
Below are MeSH descriptors whose meaning is more general than "Receptor, trkB".
Below are MeSH descriptors whose meaning is more specific than "Receptor, trkB".
This graph shows the total number of publications written about "Receptor, trkB" by people in this website by year, and whether "Receptor, trkB" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2003 | 0 | 2 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 1 | 3 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 2 | 3 |
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, trkB" by people in Profiles.
-
A, B, C's of Trk Receptors and Their Ligands in Ocular Repair. Int J Mol Sci. 2022 Nov 15; 23(22).
-
TrkB agonist antibody ameliorates fertility deficits in aged and cyclophosphamide-induced premature ovarian failure model mice. Nat Commun. 2022 02 17; 13(1):914.
-
Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib. Cancer Genet. 2022 01; 260-261:46-52.
-
Adjuvant Maintenance Larotrectinib Therapy in 2 Children With NTRK Fusion-positive High-grade Cancers. J Pediatr Hematol Oncol. 2021 Oct 01; 43(7):e987-e990.
-
Durable Response to Larotrectinib in a Child With Histologic Diagnosis of Recurrent Disseminated Ependymoma Discovered to Harbor an NTRK2 Fusion: The Impact of Integrated Genomic Profiling. JCO Precis Oncol. 2021; 5.
-
TrkB Signaling Influences Gene Expression in Cortistatin-Expressing Interneurons. eNeuro. 2020 Jan/Feb; 7(1).
-
Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Res. 2018 06 15; 78(12):3233-3242.
-
Targeting TRK family proteins in cancer. Pharmacol Ther. 2017 May; 173:58-66.
-
TRiC subunits enhance BDNF axonal transport and rescue striatal atrophy in Huntington's disease. Proc Natl Acad Sci U S A. 2016 09 20; 113(38):E5655-64.
-
TrkB agonist antibody pretreatment enhances neuronal survival and long-term sensory motor function following hypoxic ischemic injury in neonatal rats. PLoS One. 2014; 9(2):e88962.